对于非缺血性心力衰竭中的GLP1R激活剂的遗传证据
Nhu Ngoc Le1, Dipender Gill2, Sandosh Padmanabhan1
1BHF Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow G12 8TA, UK.
ESC heart failure
|March 13, 2026
概括
葡萄糖类-1受体 (GLP1R) 激动剂显示出对心力衰竭 (HF) 的保护作用,特别是在非缺血性心力衰竭中,具有保存的喷射分数 (ni-HFpEF). 这些好处超出了血糖控制范围,表明更广泛的心血管优势.
科学领域:
- 心血管医学 心血管医学
- 药物基因组学 药物基因组学
- 代谢性疾病研究研究
背景情况:
- 已知类似葡萄糖-1受体 (GLP1R) 激动剂可减少肥胖和2型糖尿病患者的心血管事件.
- 最近的临床试验表明,GLP1R激动剂在心力衰竭中提供了症状和功能上的改善,并保留了喷射分数 (HFpEF).
- 这些好处背后的确切机制,无论与血糖控制,减肥或其他途径有关,仍在调查中.
研究的目的:
- 研究GLP1R激活的遗传基础及其与各种形式的心力衰竭 (HF) 的关联.
- 确定GLP1R激活对心血管的益处是否超出了血糖控制和减肥.
- 探索GLP1R激素对不同亚型的高压特征的特异性影响,包括高压pEF和降低射出分数 (HFrEF) 的高压.
主要方法:
- 利用药物点孟德尔随机化 (MR),在GLP1R位点中使用遗传变异来作为GLP1R激活的代理.
- 将GLP1R激动因子的缩小MR估计量进行标准化测量 (每0.1日志几率降低2型糖尿病[T2DM]) 以与T2DM或体重指数 (BMI) 降低效应进行比较.
- 分析了大量全基因组关联研究 (GWAS) 的汇总统计数据,用于HF,非缺血性HF (ni-HF),ni-HFpEF,ni-HFrEF和心房 (AF),主要分析使用逆变异加权,并通过加权中位数和MR-Egger方法验证.
主要成果:
- 基因代理GLP1R激活与降低整体HF,ni-HF,特别是ni-HFpEF风险显著相关.
- 观察到GLP1R激活对HF风险的影响大于单独从血糖控制中预期的,并且在规模上与BMI降低的影响相当.
- 虽然ni-HFrEF的关联在方向上是不利的,但它们在统计上并不显著;心房动显示了与BMI潜在相关的名义关联.
结论:
- 这项研究提供了强有力的遗传证据,支持GLP1R激活对心力衰竭的保护作用,特别是在ni-HFpEF亚型中.
- 这些研究结果表明,高脂蛋白蛋白质中GLP1R激活的好处是由超出血糖控制的机制调解的.
- 遗传关联的规模和亚型特异性与当前的临床试验数据一致,需要进一步调查心脏代谢HFpEF中的GLP1R激动剂.
相关概念视频
01:24Glucagon-like Receptor Agonists
1.1K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.1K
01:29Pharmacogenomics: Identification of New Drug Targets
73
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
73
01:26Heart Failure Drugs: Inotropic Agents
1.8K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.8K
01:27Transducer Mechanism: Enzyme-Linked Receptors
4.7K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
4.7K
01:15G Protein-coupled Receptors
18.9K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
18.9K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.4K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K